Market Capitalization (Millions $) |
11 |
Shares
Outstanding (Millions) |
26 |
Employees |
- |
Revenues (TTM) (Millions $) |
2 |
Net Income (TTM) (Millions $) |
-53 |
Cash Flow (TTM) (Millions $) |
-8 |
Capital Exp. (TTM) (Millions $) |
3 |
Nighthawk Biosciences Inc
We are a fully integrated biopharmaceutical company that specializes in developing and commercializing therapies to enhance the immune system's response against a wide range of diseases, including cancer and infectious diseases. Our focus is on end-to-end development and commercialization, from discovery to clinical trials and commercial pipeline. We have recently launched Scorpion Biological Services, Inc. (Scorpion), our subsidiary that enables us to enhance efficiency and decrease dependence on third-party contract research and development biomanufacturing organizations. Additionally, we are in the process of acquiring Elusys Therapeutics, Inc., which supports our development of critical therapeutic innovations for the biodefense sector.
Our main platforms are the gp96 platform and RapidVax platform, which leverage gp96 to transport predefined antigens to stimulate an immune response. We have lead assets, such as HS-110 and HS-130, in various stages of clinical trials for non-small cell lung cancer and solid tumors. The RapidVax platform allows for the accelerated customization of vaccines to respond to biological threats.
In addition, we have a platform focused on targeting the Death Receptor 3/TNF receptor superfamily member 25 (DR3/TNFRSF25) cellular receptor to restore balance to the immune system. Our lead asset, PTX-35, is being evaluated in a Phase 1 clinical trial for advanced solid tumors.
Recently, we have entered into an agreement to acquire Elusys Therapeutics, Inc., a company focused on the commercialization of ANTHIM, a monoclonal antibody antitoxin for anthrax. ANTHIM has received marketing approvals in the U.S., Canada, Europe, and the UK. This acquisition will further strengthen our biodefense capabilities.
Overall, our goal is to decrease the time and increase the efficiency of drug development to accelerate the delivery and commercialization of novel immune activating therapies.
Company Address: 627 Davis Drive, Suite 300 Morrisville 27560 NC
Company Phone Number: 240-7133 Stock Exchange / Ticker: NYSEAMER NHWK
NHWK is expected to report next financial results on March 30, 2024. |
|
|